Thromboprophylaxis in Adult General Medical Patients - Guidelines for Management
|
|
- Louisa Montgomery
- 5 years ago
- Views:
Transcription
1 Thromboprophylaxis in Adult General Medical Patients - Guidelines for Management Adapted from the Worcestershire Acute Hospitals NHS Trust Guideline WAHT-MED-010 Version: Final Ratified by: Provider Quality and Safety Committee Date ratified: July 2010 Name of originator/author: Sue Lunec, Head of Medicine Management for Provider Services Date issued for publication: September 2010 Review date: November 2012 Expiry date: September 2013 Target audience: WPCT community hospitals clinical staff and contracted clinical staff If you would like this document in other languages or formats (i.e. large print), please contact the Communications Team on or communications@worcestershire.nhs.uk WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 1 of 9
2 Acute Trust Guideline development Dr S Shafeek Approved by both Medical Directorates and by Medicines Safety Committee on Consultant Haematologist, WAHT 29 th July 2008 Community Hospital Guideline Development Key individuals involved in adapting the Acute Trust Guidelines for use in community hospitals Name Dr S Shafeek Ruth Prince Sue Lunec Designation Consultant Haematologist, WAHT Clinical Pharmacist for Community Hospitals Head of Medicines Management Circulated to the following individuals for consultation Name Dr Sumit Bhaduri Finbarr Costigan Lisa Levy Maria Wilday Sue LaHiff Ginny Snape Karen Young Linda Ingles Della Lewis Carole Clive Vicky Preece Lesley Way Rosemary Pickford Sue Chauhan Designation Joint Medical Director Joint Medical Director Associate Director of Provider Services Matron/Hospital Manager PWCH Matron Evesham CH Matron Tenbury CH Matron Pershore CH Matron Malvern CH Clinical Governance Team Manager Consultant Nurse Infection Control Associate Director of Nursing and Therapies Patient Safety Manager Clinical Pharmacist for Community Hospitals Clinical Pharmacist for Community Hospitals WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 2 of 9
3 Guideline for thromboprophylaxis in adult (18yrs and older) general medical patients INTRODUCTION Venous thrombosis is a condition in which a blood clot (thrombus) forms in a vein. This can reduce the blood flow through the affected vein, sometimes but not always causing swelling and pain. Venous thrombosis most commonly occurs in the deep veins in the legs, thighs, or pelvis. It is usually referred to as deep vein thrombosis (DVT). An embolism is created if all or part of a clot is dislodged from its original site and travels through the venous system. If the clot lodges in the lung, a very serious condition, pulmonary embolism (PE), arises and can easily cause sudden death. Up to 10% of all hospital deaths could be caused by a PE 1. Venous thrombosis can form in any part of the venous system but DVT and PE are the most common and are known as venous thromboembolism (VTE). Each year over 25,000 people in England alone die from VTE contracted in hospital. This has been the subject of a recent Government Health Select Committee report 2. Historically VTE has been considered to be a problem only in surgical patients. This is not the case as available data confirm that acutely ill medical patients are at the same risk, if not more, than surgical patients 3,4. This situation requires a deliberate and ongoing strategy to educate and inform healthcare professionals of the need for adequate risk assessment and actions to promote VTE prevention in all adult inpatients 2,5.. VTE is a condition that can be reduced, provided that an adequate risk assessment forms part of our day to day routine. DVT/PE are to be included in the Healthcare Commissions annual inspection. GUIDELINE VTE is largely preventable and in surgical patients prophylaxis with LMWH has been proven to be safe and cost-effective. Randomised trials have consistently demonstrated that appropriate use of pharmacological thromboprophylaxis can also reduce the risk of VTE in medical patients. 3 key trials, MEDENOX 4, PREVENT 6 and ARTEMIS 7 have shown risk reduction of DVT of 50-65% with appropriate use of thromboprophylaxis in medical patients. Combined results of these trials show that medical patients are at high risk of VTE when immobilised with acute medical illnesses, and this risk can be reduced by the use of pharmacological prophylaxis with LMWHs. Medical thromboprophylaxis is a grade 1 recommendation in the ACCP 3 guidelines and is recommended in both SIGN 8 and THRIFT II 9 consensus group guidelines and ther Department of Health. These guidelines all recommend the use of pharmacological thromboprophylaxis in acutely ill medical patients who exhibit risk factors for VTE in whom there is no contraindication. SCOPE This guideline should be used by Worcestershire PCT medical and nursing staff and people contracted to work for the PCT including GPs, involved in the care of adult inpatients with an acute medical condition. WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 3 of 9
4 ASSESSMENT OF PATIENTS The Department of Health assessment sheet should be completed by the doctor, for each patient and filed in their notes. For those patients in community hospital settings for long periods of time there is potential for their medical condition to deteriorate from stable to acutely unwell. In cases where the initial acute medical condition has been treated and resolved, staff must be aware of the possibility that a patient s medical condition may deteriorate, and in these cases the risk of thrombosis may increase. In such cases it may be appropriate to restart enoxaparin, and monitor the patient s progress closely. RISK FACTORS for VTE Active cancer or cancer treatment Active heart or respiratory failure Acute medical illness Age over 60 years Antiphospholipid syndrome Behcet s disease Central venous catheter in situ Immobility (for example, paralysis or limb in plaster) Inflammatory bowel disease (for example, Crohn s disease or ulcerative colitis) Myeloproliferative diseases Risk Factors for VTE 10 Nephrotic syndrome Obesity (body mass index 30 kg/m2) Paraproteinaemia Paroxysmal nocturnal haemoglobinuria Personal or family history of VTE Pregnancy or puerperium Recent myocardial infarction or stroke Severe infection Use of oral contraceptives or hormonal replacement therapy Varicose veins with associated phlebitis Inherited thrombophilias WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 4 of 9
5 The following flowchart should be used when deciding whether a medical patient should be prescribed enoxaparin for thromboprophylaxis: Is the patient an adult who is acutely ill (likely to be immobilised for 3 or more days) with one or more VTE risk factors? YES Is low molecular weight heparin contraindicated? NO YES Give enoxaparin (Clexane) 40mg* once daily s/c (* review dose at extremes of body weight) Consider mechanical thromboprophylaxis with graduated compression stockings (GCS) Contraindications to enoxaparin Creatinine clearance <30ml/min (consider s/c unfractionated heparin (UFH) or a reduced dose of enoxaparin High risk of bleeding A known bleeding disorder/ thrombocytopenia History of heparin induced thrombocytopenia On oral anticoagulants with a therapeutic INR (INR > 2.0) Recent spinal or epidural analgesia. Hemorrhagic stroke or risk of CNS bleed. Ischaemic stroke within one week of onset Aortic aneurysm Acute bacterial endocarditis hypersensitivity to either enoxaparin sodium, heparin or its derivatives including other Molecular Weight Heparins WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 5 of 9
6 Continuation of thromboprophylaxis Thromboprophylaxis once commenced should be continued until the patient is fully ambulant. It should be regularly reviewed and only continued after ambulation if the risk of VTE is still high. Please note that enoxaparin is only licensed for use for 14 days. There is positive evidence for use longer than 14 days but the benefit of a reduction in venous thromboembolic events has to be balanced against an increase in the risk of bleeding. The patient should therefore be re-assessed and this should be documented in the patient s notes Monitoring of LMWH The standard prophylactic regimen does not require monitoring 11 Graduated compression stockings (GCS) The decision to fit GCS should be made in collaboration with the medical staff. The patient should be measured accurately in order to ascertain the correct size of the stocking. If they are fitted incorrectly, they may be too tight, restricting the circulation, causing a tourniquet effect and thus predisposing to DVT. If they are too loose they will be completely ineffective. It is important to note that even if GCS are fitted correctly they are not 100% effective at preventing DVT. Other preventative measures such as passive leg exercises should be encouraged where appropriate. Contraindications to compression stockings Gross leg oedema Gross pulmonary oedema Ischaemic vascular disease Local leg conditions e.g. gangrene, dermatitis, skin grafts Extreme leg deformity MONITORING TOOL There will be an audit of medical records to measure compliance with these guidelines. STANDARDS % CLINICAL EXCEPTIONS All medical inpatients (aged >18years) who meet the inclusion criteria will receive appropriate thromboprophylaxis 100% None WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 6 of 9
7 REFERENCES 1. Cooper JW & Groce J III. DVT/PE prophylaxis in medically ill patients: a new avenue of clinical management in the long term care setting.consult pharm 2001; 16 (suppl D): House of Commons Health Select Committee.In :The prevention of venous thromboembolism in hospitalised patients, HC99, The Stationary Office Limited, London, England Geerts WH et al. Prevention of venous thromboembolism. The Seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 2004; 126:338S-400S. 4. Samama MM et al. A comparison of Enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. (MEDENOX) N Eng J Med 1999; 341: Cohen A T et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients Thromb Haemo 2005; 94: Leizorovicz A et al. Randomised, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: Cohen A T et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 2006; 332: Scottish and Collegiate Guideline Network (SIGN). Prophylaxis of Venous Thromboembolism. London. SIGN Publication 2002: no.62. Available at 9. Thromboembolic Risk Factors (THRIFT II) Consensus Group Guidelines. Available at NICE Guideline: CG46 Venous thromboembolism 23 April BNF, September 2007 WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 7 of 9
8 Equality Impact Assessment Report Template Name of policy or function - Guideline for thromboprophylaxis in adult (18yrs and older) general medical patients Responsible Manager - Sue Lunec, Head of Medicine Management Date EIA completed - 2 March 2010 Description of aims of function/policy - To improve the health of patients in the community hospitals; To fulfil the requirement of national guidance o Brief summary of research and relevant data - See references o Methods and outcomes of consultation o Results of Initial Screening or Full Equality Impact Assessment Initial or Full Equality Impact Assessment? Equality Group Race Gender Disability Age Sexual Orientation Religion or Belief Human Rights Initial Assessment of Impact 1. Decisions and or recommendations (including supporting rationale) 2. Equality action plan (if required) 3. Monitoring and review arrangements (include date of next full review) WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 8 of 9
9 Department Medicines Management Directorate Medicines Management Director Dr S Bhaduri Report produced by and job title Sue Lunec, Head of Medicines Management Date report produced March 2010 Date report published September 2010 WPCT Thromboprophylaxis guideline adapted from WHAT guideline WHAT-MED-010 Page 9 of 9
Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationGUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY
GUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY SEE SEPARATE GUIDELINES FOR THROMBOPROPHYLAXIS IN OBSTETRICS This guidance does
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationNew v1.0 Date: December 2015 Patricia Wain - Associate Director Physical Care. Kenny Laing - Deputy Director of Nursing
Clinical Venous Thromboembolism: Standing Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: New v1.0 Date: December 2015 Patricia Wain - Associate Director Physical
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationVenous thromboembolism - reducing the risk
Venous thromboembolism - reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE guideline Draft for consultation,
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationVenous thromboembolism: reducing the risk
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationVenous thromboembolism
Issue date: April 2007 Venous thromboembolism Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery) NICE clinical guideline 46 Developed
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More information1.0 PATIENT CARE Including Physical Healthcare
SECTION: 1.0 PATIENT CARE Including Physical Healthcare POLICY /PROCEDURE: 1.33 NATURE AND SCOPE: SUBJECT: PROCEDURE - TRUST WIDE VENOUS THROMBOEMBOLISM (VTE) This procedure details Venous Thromboembolism
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Reference No: P_CS_05 Version 2.4 Ratified by: LCHS Trust Board Date ratified: 27 th January 2015 Name of originator / author: Medical Director Name of responsible
More informationVenous thromboembolism (VTE), which includes
C l i n i c a l R e v i e w A r t i c l e Prevention of Venous Thromboembolism in Hospitalized Medical Patients Brian S. Wojciechowski, MD David A. Cohen, MD Venous thromboembolism (VTE), which includes
More informationVenous Thromboembolism Policy (VTE)
Venous Thromboembolism Policy (VTE) DOCUMENT CONTROL: Version: 2 Ratified by: Clinical Effectiveness Committee Date ratified: 5 November 2013 Name of originator/author: Modern Matron St John s Hospice
More informationVTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism)
VTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism) When using this document please ensure that the version you are using is the most up to date either by checking on the Trust
More informationVenous Thromboembolism Policy (VTE)
Venous Thromboembolism Policy (VTE) DOCUMENT CONTROL: Version: v3 Ratified by: Clinical Quality Group Date ratified: 2 February 2016 Name of originator/author: Modern Matron St John s Hospice Name of responsible
More informationPULMONARY EMBOLISM MANAGEMENT GUIDELINES
PULMONARY EMBOLISM MANAGEMENT GUIDELINES This document is adapted from the NICE guidelines titled Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationPrevention and treatment of venous thromboembolic disease
REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationUtilization of DVT Prophylaxis in non ICU Hospitalized Patients
Asian Pacific Journal of Tropical Disease (2012)S707-S711 707 Contents lists available at ScienceDirect Asian Pacific Journal of Tropical Disease journal homepage:www.elsevier.com/locate/apjtd Document
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationPreventing Blood Clots in Adult Patients
Manchester Royal Eye Hospital Surgical Services Information for Patients Preventing Blood Clots in Adult Patients This leaflet will give you information on how to reduce the risk of developing blood clots
More informationSuspected Deep Vein Thrombosis (DVT) Pathway for Non Pregnant patients Updated November 2016, with new D-dimer reference range
Suspected Deep Vein Thrombosis (DVT) Pathway for Non Pregnant patients Updated November 2016, with new D-dimer reference range Suspect a DVT? Complete a Two-level DVT Wells score on ICE system (see page
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationGuideline Quick View: Venous Thromboembolism
Guideline Quick View: Venous Thromboembolism The AORN Guideline Quick View is a key component of Guideline Essentials, a suite of online implementation tools designed to help the perioperative team translate
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationMMP016 POLICY FOR PRIMARY THROMBOPROPHYLAXIS FOR PATIENTS ADMITTED TO NHFT
MMP016 POLICY FOR PRIMARY THROMBOPROPHYLAXIS FOR PATIENTS ADMITTED TO NHFT MMP016 Policy for primary thromboprophylaxis for patients admitted to NHFT (rev Sept 2020) Page 1 of 21 Table of Contents Why
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationSuspected Deep Vein Thrombosis (DVT) Assessment
CHI no... First name... DOB... /... /... Last name... Sex: c M c F Address...... Telephone... or attach addressograph label here Hospital/Location: c Hairmyres c Monklands c Wishaw Other (specify)... Ward/Base...
More informationA Prospective, Controlled Trial of a Pharmacy- Driven Alert System to Increase Thromboprophylaxis rates in Medical Inpatients
University of New Mexico UNM Digital Repository Undergraduate Medical Student Research Papers Health Sciences Center Student Scholarship 8-20-2009 A Prospective, Controlled Trial of a Pharmacy- Driven
More informationDeep vein thrombosis: diagnosis, prevention and treatment
Deep vein thrombosis: diagnosis, prevention and treatment Catherine Bagot BSc, MD, MRCP, FRCPath and Campbell Tait BSc, FRCP, FRCPath Deep vein thrombosis can lead to significant morbidity and has well-recognised
More informationHow to prevent blood clots whilst in hospital and after your return home
How to prevent blood clots whilst in hospital and after your return home Patient information WHAT What IS is DEEP deep VEIN vein THROMBOSIS? thrombosis? Deep Vein Thrombosis DVT is a blood clot within
More informationVTE Prophylaxis. NEW NICE guidance. Providing venous thromboembolism (VTE) prophylaxis to all at risk hospital patients
NEW NICE guidance NICE guidance (MTG19) supports the use of the geko device for people who have a high risk of VTE and for whom pharmacological or other mechanical methods of VTE prevention are impractical
More informationVenous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Nursing A guide for patients and carers Contents Why do blood clots form in veins?... 1 How common is a deep vein thrombosis (DVT) or pulmonary embolus (PE)?... 2 How are DVTs/
More informationDeep Vein Thrombosis and Pulmonary Embolism: Patient Information
Deep Vein Thrombosis and Pulmonary Embolism: Patient Information A Deep Vein Thrombosis (DVT) and a Pulmonary Embolism (PE) are both disorders of unwanted blood clotting. Unwanted blood clots can occur
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationDeep Vein Thrombosis and Pulmonary Embolism: Risks, Prevention & Treatment
Deep Vein Thrombosis and Pulmonary Embolism: Risks, Prevention & Treatment Other formats If you need this information in another format such as audio tape or computer disk, Braille, large print, high contrast,
More informationComparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project
Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project Dr. Jonathan Laxton, FRCPC, R5 GIM University of Manitoba
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationThe Royal College of Emergency Medicine. VTE Risk in Lower Limb Immobilisation in Plaster Cast 2015/2016
The Royal College of Emergency Medicine Clinical Audits VTE Risk in Lower Limb Immobilisation in Plaster Cast Introduction 2015/2016 EXCELLENCE IN EMERGENCY MEDICINE A significant number of patients attend
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationProphylaxis for Hospitalized and Non-Hospitalized Medical Patients
Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric
More informationTrust Policy. Venous Thromboembolism (VTE) Risk Assessment and Prophylactic Treatment. Dr Allison Tso, Consultant Haematologist Version 3.
Trust Policy Venous Thromboembolism (VTE) Risk Assessment and Prophylactic Treatment Author(s) Dr Allison Tso, Consultant Haematologist Version 3.1 Version Date March 2013 Implementation/approval Date
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationTHROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS. 362 Version No: 2 Previous Trust / LHB Ref No:
Reference No: THROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS 362 Version No: 2 Previous Trust / LHB Ref No: 362 Documents to read alongside this Policy, Procedure etc (delete as necessary)
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationVTE Prophylaxis. NICE guidance. Providing venous thromboembolism (VTE) prophylaxis to all at risk hospital patients
NICE guidance NICE guidance (MTG19) supports the use of the geko device for people who have a high risk of VTE and for whom pharmacological or other mechanical methods of VTE prevention are impractical
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationMutidisciplinary cooperation on VTE prevention and managment
Mutidisciplinary cooperation on VTE prevention and managment TAO YANG Dpartment of vascular surgery Shanxi DAYI Hospita Tai yuan Shanxi China Disclosure Speaker name: Tao Yang... I have the following potential
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationConfirmed blood clot
n The Leeds Teaching Hospitals NHS Trust Confirmed blood clot (Deep vein thrombosis and pulmonary embolism) Information for patients Please read this leaflet carefully. It will give you information about
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationVenous Thrombo-Embolism (VTE)
Venous Thrombo-Embolism (VTE) Information for service users and carers RDaSH leading the way with care Older People s Mental Health Services Reducing risk of unwanted blood clots whilst in hospital About
More informationDeep vein thrombosis (DVT) and pulmonary embolism (PE) advice for ophthalmic surgery patients
Deep vein thrombosis (DVT) and pulmonary embolism (PE) advice for ophthalmic surgery patients What is a deep vein thrombosis (DVT)? A DVT is a blood clot that forms within a vein deep in the leg but can
More informationCommissioning Policy. Treatment of Snoring. April 2010
Commissioning Policy Treatment of Snoring April 2010 This commissioning policy applies to patients within: South Worcestershire Clinical Commissioning Group (CCG) Redditch & Bromsgrove Clinical Commissioning
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationVENOUS THROMBOEMBOLISM PROPHYLAXIS POLICY
VENOUS THROMBOEMBOLISM PROPHYLAXIS POLICY Document Author Written By: Senior Pharmacist Medicines Information Date: January 2016 Authorised Authorised By: Chief Executive Date: 8 March 2016 Lead Director:
More informationMeasurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI
Measurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI Hospitals For hospitals in the United States, measures of cardiovascular care mandated by the Joint Commission have recently
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More information